Quick Answer
ImmunityBio, Inc. reported Cash And Cash Equivalents At Carrying Value of $88.33 million for the year ending 2025.
- ImmunityBio, Inc. showed a decrease of -38.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from ImmunityBio, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: $3.99 million | Q3 2014: $3.18 million | Q1 2015: $49.85 million | Q2 2015: $120.44 million | Q3 2015: $358.62 million | Q1 2016: $63.25 million | Q2 2016: $38.22 million | Q3 2016: $31.40 million | Q1 2017: $13.60 million | Q2 2017: $39.04 million | Q3 2017: $16.12 million | Q1 2018: $11.20 million | Q2 2018: $16.12 million | Q3 2018: $15.31 million | Q1 2019: $22.28 million | Q2 2019: $17.28 million | Q3 2019: $18.29 million | Q1 2020: $58.65 million | Q2 2020: $115.16 million | Q3 2020: $84.69 million | Q1 2021: $44.68 million | Q2 2021: $83.96 million | Q3 2021: $64.52 million | Q1 2022: $36.39 million | Q2 2022: $61.90 million | Q3 2022: $104.16 million | Q1 2023: $88.48 million | Q2 2023: $43.51 million | Q3 2023: $177.96 million | Q1 2024: $133.04 million | Q2 2024: $130.10 million | Q3 2024: $111.97 million | Q1 2025: $60.66 million | Q2 2025: $137.66 million | Q3 2025: $60.24 million.
- Over the full 14 years of available data (2012 to 2025), ImmunityBio, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 76,050.0%.
- Historical annual values: Fiscal year 2025: $88.33 million | Fiscal year 2024: $143.43 million | Fiscal year 2023: $265.45 million | Fiscal year 2022: $104.64 million | Fiscal year 2021: $181.10 million | Fiscal year 2020: $34.92 million | Fiscal year 2019: $75.80 million | Fiscal year 2018: $16.82 million | Fiscal year 2017: $23.87 million | Fiscal year 2016: $8.08 million | Fiscal year 2015: $175.91 million | Fiscal year 2014: $59.10 million | Fiscal year 2013: $350.0 thousand | Fiscal year 2012: $116.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: